A lthough CEBPA double-mutated (CEBPA DM ) acute myeloid leukemia is considered to be a favorable-risk disease, relapse remains a major cause of treatment failure. Most CEBPA DM patients have a classic biallelic mutant combination with an N-terminal mutation leading to production of p30 protein plus a C-terminal loss-offunction in-frame indel mutation (CEBPA Classic-DM ), but approximately onethird of cases have one or more non-classic mutations, with diverse combinations reported, and there is little information on the consequences of such mutants. We evaluated outcome in a cohort of 104 CEBPA DM patients, 79 CEBPA Classic-DM and 25 with non-classic mutants, and found that the latter may have poorer survival (5-year overall survival 64% vs. 46%; P=0.05), particularly post relapse (41% vs. 0%; P=0.02). However, for this analysis, all non-classic cases were grouped together, irrespective of mutant combination. As CEBPA DM cases have been reported to be hypermethylated, we used methylation profiling to assess whether this could segregate the different mutants. We developed a CEBPA 
Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment Introduction
The CEBPA gene encodes CCAAT/enhancer binding protein-α (C/EBPα), a basic leucine zipper (bZIP) transcription factor that is essential for hematopoietic stem cell regulation and myeloid development. 1, 2 The gene is mutated in approximately 8% of acute myeloid leukemia (AML) patients with intermediate-risk cytogenetics, and presence of biallelic double mutations (CEBPA DM ) in the absence of an FLT3 internal tandem duplication (FLT3 ITD ) is associated with a favorable prognosis. [3] [4] [5] [6] [7] [8] [9] In the current risk-adapted therapy strategies for AML, [10] [11] [12] these patients are classified as good-risk and therefore not usually considered for consolidation of first remission by allogeneic transplantation. 11, 13 Mutations occur throughout the single exon gene but predominate at the N and C termini.
14 N-terminal mutations are nearly always frameshift or nonsense mutations causing increased translation from an internal ATG start site and production of a truncated p30 protein that retains the same reading-frame as the full-length p42 protein but lacks the first transactivation domain (TAD1). The most common C-terminal mutations are in-frame indels in the bZIP DNA binding domain (DBD) or leucine zipper domain (LZD) that lead to loss of the ability to bind to DNA or dimerize, classified here as C-terminal loss-offunction (C-LOF). However, many other mutations have also been reported, including missense mutations in the DBD or LZD, missense mutations and in-frame indels in the mid-region, and frameshift or nonsense mutations in the mid-region or C-terminus. Some also present as homozygous alterations due to chromosome 19 uniparental disomy. 15, 16 The most common combination of mutations is an N-terminal frameshift on one allele plus a C-terminal in-frame indel on the other allele that together are predicted to lead to complete loss of normal p42 C/EBPα activity, 14 21 CEBPA DM cases also form distinct epigenetic clusters with a markedly hypermethylated profile. 22, 23 But although CEBPA SIL cases also have a hypermethylated profile, this segregates from the CEBPA DM cluster and, interestingly, they appear to be associated with a biologically distinct subtype of AML with a poor prognosis. 21, 22, 24 Potential methylation differences according to the underlying combination of CEBPA mutants, however, have not been reported.
In order to investigate potential differences between CEBPA DM mutant combinations, we evaluated clinical outcome in 104 CEBPA DM cases (79 CEBPA Classic-DM and 25 with non-classic mutants) and observed that the non-classic cases may have a lower overall survival (OS). However, the number of cases was relatively small and all cases with a non-classic mutant were included in this group, irrespective of the mutant type. We therefore investigated whether methylation profiling of samples from doublemutated patients could assist in segregating the different mutant combinations.
Methods

Patient cohorts
The patients investigated were younger adults entered into the UK MRC AML10, AML12 and AML15 trials. Figure S1 ). Selected tests were performed on a further 82 samples with specific cytogenetic and molecular abnormalities.
Therapy, clinical end points and statistical methods
Details of clinical protocols, end points and statistical methods are defined in the Online Supplementary Appendix.
Methylation arrays and data processing
DNA was bisulfite-converted using the EZ DNA MethylationGold Kit (Zymo Research, California, USA) and random samples checked by methylation-specific PCR to ensure efficient conversion (see the Online Supplementary Appendix). Methylation profiling was performed using the Illumina Infinium HumanMethylation27 (n=40, cohort 1) and HumanMethylation450 (n=95, cohort 2) BeadChip arrays (Illumina Inc., California, USA). Details of data processing are given in the Online Supplementary Appendix. Derived β values were expressed as the percentage methylation at a given CpG probe. Selected CpG sites were further analyzed using pyrosequencing assays (see the Online Supplementary Appendix).
Unsupervised analysis of patient methylation profiles
In a given sample, probes were defined as methylated if the β value was more than 0.3, unmethylated if 0.3 or under. 25 Samples were clustered based on their β values at probes displaying significant variation (variable probes), as previously defined. 25, 26 They were defined as variable if methylated in 1 sample or more plus unmethylated in 1 sample or more. CpG islands (CGIs) were located as previously defined; 27 their methylation levels were derived by calculating the mean β value of probes at these locations. Hierarchical clustering was performed using the Euclidian distance of β values and Ward algorithm in R. 
Derivation and analysis of
Mutant CEBPA level and confirmation of biallelic status
Mutant CEBPA level was quantified as previously described 6 or approximated from the sequence chromatogram (average height of ≥5 peaks). Monoallelic/biallelic status was investigated by sequencing clones derived from full-length CEBPA amplicons as previously described.
Results
Clinical outcome in CEBPA DM cases according to mutant type
Of the 104 CEBPA DM cases evaluated, 79 had classic and 25 had non-classic mutants (Table 1 and Online  Supplementary Table S1 ). The latter included 4 patients predicted to produce p30 plus a C-terminal missense mutant, 8 with combinations predicted to produce just p30, and 13 with different combinations predicted to produce just a C-LOF protein. 
CEBPA genotype* Number Predicted functional consequence
Clinical cohort CEBPA
WT variate analysis, there was no significant difference in relapse-free survival or relapse rate (RR). However, there was a trend towards a lower OS in the non-classic cases (64% vs. 46% at 5 years, P=0.05) ( Figure 1A) , which was largely due to the worse outcome post-relapse in the nonclassic cases. The proportion of relapsing patients who achieved a second remission did not differ between the groups (61% vs. 55%), but 5-year survival post relapse was 41% versus 0% (P=0.02) ( Figure 1B) , and 59% versus 0% from second remission (P=0.004) ( Figure 1C ). The survival differences were not, however, statistically different in multivariate analysis (Table 2 ), but this is not surprising given the small group sizes. Although the significantly higher proportion of DNMT3A-mutated cases in the nonclassic group could have contributed to their worse outcome, as both these mutations and FLT3 ITD adversely impact on the favorable outcome associated with CEBPA DM AML, 6,28 the trend towards a lower OS in the non-classic cases was still present when patients with these mutations were excluded (70% vs. 53%; Hazard Ratio 1.95, 95% confidence intervals 0.95-4.01; P=0.08) ( Figure 1D ).
Development of a CEBPA Classic-DM methylation signature
The clinical evaluation grouped all non-classic cases together in order to obtain an adequate number of patients for analysis, but this cohort, therefore, included patients with many mutant combinations predicted to have differing functional consequences. In order to explore potential methods for discriminating between these combinations, we investigated the impact of mutant type on methylation profiles. A preliminary cohort of samples from 40 
NPM1
WT patients in our earlier study. 6 The array data were validated by pyrosequencing assays at four differentially methylated CpG sites (Online Supplementary Figure S2 ). Most CpG sites analyzed showed little variation in methylation levels across the whole cohort, but unsupervised cluster analysis according to levels of the most variably methylated probes revealed two main clusters. All 10 CEBPA DM samples, including two non-classic cases, fell in the cluster of 16 samples with significantly higher levels of mean CGI methylation (Figure 2A) , and the mean level of CGI methylation was significantly different between CEBPA Classic-DM and CEBPA WT samples ( Figure 2B) their distance scores, the CEBPA Classic-DM samples formed a distinct group that were clearly separate from the CEBPA WT samples ( Figure 3A Figure S3) . Using supervised analysis according to the derived CEBPA Classic-DM and CEBPA WT signatures, the same 16 CEBPA DM cases had a methylation profile that was closest to the CEBPA Classic-DM signature with a wide difference between the two signatures ( Figures 3B and 4) , indicating that their profile was equivalent to the CEBPA Classic-DM cases in cohort 1. Further analysis of the one CEBPA Classic-DM case that fell closer to the CEBPA WT group indicated that the mutations were biallelic but only approximately half of the cells in the sample carried mutations; mean mutant level was 28% for the pair, which was the lowest mean level of all 25 CEBPA Classic-DM cases (median 44%; range: 28-50%). The methylation profile of this case could, therefore, have been affected by the presence of a significant proportion of non-leukemic cells and it was excluded from further analyses. Using the distance scores (mean±2SD) for CEBPA Classic-DM cases in cohort 1, tests showed that these scores classified CEBPA Classic-DM and CEBPA WT genotypes in the second cohort with 95% accuracy, 88% sensitivity, and 100% specificity. The distance scores of the 24 CEBPA Classic-DM cases from the combined cohorts were then used to define a CEBPA Classic-DM quadrant that segregated all CEBPA Classic-DM cases from CEBPA WT cases ( Figure 3C ).
Investigation of the CEBPA Classic-DM methylation signature in other good-risk patients
In order to examine whether the CEBPA Classic-DM methylation signature could simply reflect 'good-risk' disease or be due to a lack of C/EBPα expression, methylation levels at three differentially methylated CpG sites from the signature were quantified by pyrosequencing using samples from 21 patients with inv(16) and 19 with t(8;21), both associated with down-regulated C/EBPα expression, [29] [30] [31] and 42 with NPM1
MUT
FLT3
WT . KHNYN and VAMP5 were more hypermethylated in the CEBPA Classic-DM signature, while LY9 was more hypomethylated. Each subgroup differed significantly from the 24 CEBPA Classic-DM cases at two of the three sites (Online Supplementary Figure S4) . A composite methylation score was calculated for each sample; it was statistically significantly different from the CEBPA Classic-DM cases for all three subgroups ( Figure 5 ), indicating that the methylation profile was a distinct feature of the mutant proteins that lead to total loss of normal C/EBPα function rather than absence of C/EBPα per se.
Investigation of non-classic CEBPA
DM and CEBPA
SM mutants
Having established that CEBPA Classic-DM cases have a methylation profile that is distinct from CEBPA WT cases, profiles of 14 CEBPA DM cases with a variety of different non-classic combinations were investigated using the HumanMethylation450 array (Methylation cohort 2) ( Table 1) . On unsupervised analysis, 9 (64%) were hypermethylated and 5 (36%) hypomethylated (Online Supplementary Figure S3) . To assess their impact on the CEBPA methylation signatures, these 14 cases and the 2 non-classic cases from the initial cohort were considered according to the predicted functional consequence of the combination.
Six cases were predicted to produce just p30 protein, with a classic N plus null mutant (mid-region or C-terminal frameshift/nonsense) combination. Only 1 fulfilled the CEBPA Classic-DM criteria; 4 fell outside this quadrant but were still distinct from CEBPA WT cases, and 1 grouped with the CEBPA WT cases ( Figure 6A ). Three cases were predicted to just give rise to classic C-LOF proteins without p30 (2 homozygous classic C, 1 compound heterozygous with a classic C plus C-frameshift combination). Two fulfilled the CEBPA Classic-DM criteria and 1 was intermediate between CEBPA
Classic-DM and CEBPA
WT
. The 7 cases with missense mutations were also highly variable. Three had a classic N plus C-missense combination; none fulfilled the CEBPA Classic-DM criteria, 2 were intermediate between the signatures, and 1 grouped with CEBPA WT cases. Mutant levels were indicative of 80% or more mutated cells in all 3 cases; 2 were biallelic by cloning but no full-length amplicons could be obtained in 1 case. Similarly, only 1 of the 3 homozygous C-missense cases fell in the CEBPA Classic-DM quadrant, the other 2 were equivalent to CEBPA WT cases. The remaining case was compound heterozygous with a classic C and C-missense combination, and this did fulfil the CEBPA Classic-DM criteria. These results suggest that the functional consequence of double-mutated cases producing at least 1 non-classic mutant protein can be highly variable and difficult to predict. Of note, when outcome was assessed in the non-classic cases according to their methylation profile, there was Figure S3) . On supervised analysis, all except 2 cases were equivalent to CEBPA WT cases, with no obvious grouping according to the type of mutant (Figures  4 and 6B) . The remaining 2 cases fell in or close to the CEBPA Classic-DM quadrant; both had a classic C mutation. It is possible that the CEBPA WT allele had been silenced in these cases, but RNA samples were not available to check this.
Discussion
Molecular genotyping is increasingly used to risk stratify patients with AML, but clinical application of this information needs to be accurate and robust for optimal patient therapy. This is particularly important for good-risk patients such as those with biallelic CEBPA mutations, where the current recommendation is not to proceed to transplantation in first remission, as for some patients this could lead to undertreatment. Identifying those who are at greater risk of relapse and poorer survival may, therefore, guide patient management. Very limited information is available on the impact of the different CEBPA mutations, with all CEBPA DM cases currently being classified as goodrisk, irrespective of the underlying mutant. However, mutations identified in approximately one-third of CEB-PA DM patients do not conform to the classic combination of N-terminal frameshift or nonsense mutation plus C-terminal in-frame indel. As many of the other mutations are unique and of unknown functional consequence, determining their significance is challenging, particularly in view of the multiple functions attributed to C/EBPα.
1,2
Although we had access to a database of 2162 patients with known CEBPA genotype and available clinical data from three consecutive UK MRC trials of younger adult patients with AML, 67% with intermediate-risk cytogenetics, we were still able to evaluate long-term outcome in a cohort of only 79 CEBPA Classic-DM cases and 25 CEBPA DM cases with at least one non-classic mutant. The results suggested that the non-classic cases may have a poorer outcome; in particular, none of these cases survived after relapse. These results may be influenced by differences in the coincident mutations in the two groups. The majority of recurrent mutations with known prognostic significance in AML are uncommon in CEBPA DM cases, 32 and for many of them their impact in this subgroup is, therefore, not well defined. Both FLT3 ITD and DNMT3A mutations adversely impact on the favorable outcome of CEBPA DM AML. 6, 28 But even when patients with these mutations were excluded from the analysis, OS for the non-classic cases was still worse. The incidence of GATA2 mutations was non-significantly lower in the non-classic cases, but although one study reported that they are associated with better OS, 33 most studies, including our own, observed no difference. 34, 35 There was a non-significantly higher incidence of TET2 mutations in the non-classic cases, but their impact is unclear, with only one study reported specifically for CEBPA DM AML that showed a worse OS but not event-free survival in TET2
MUT cases. 33 Clearly, many more cases would need to be analyzed in order to take into account coincident mutations other than FLT3 ITD and DNMT3A mutations.
A wide range of non-classic mutations was observed and, for the outcome analysis, sufficient patient numbers could only be obtained by grouping all the non-classic patients together, which precluded evaluation of specific mutant combinations. We, therefore, sought alternative methods of assessment and, as CEBPA DM patients have a distinct hypermethylated profile, 22, 23 investigated whether genome-wide methylation profiling could provide information on the more broad-spectrum functional consequence of different mutants. We confirmed the relatively hypermethylated profile associated with a CEBPA DM geno- Classic-DM cases studied clearly separating from the CEBPA WT cases. The remaining case contained a significant proportion of non-mutated cells, which provided indirect evidence that the signatures reflected CEBPA genotype. The signatures were a distinct feature of mutant C/EBPα and could not simply be attributed to a lack of C/EBPα, as they were not replicated in samples from patients with core-binding factor leukemias that are associated with downregulation of CEBPA expression. Presence of at least a minimal level of C/EBPα activity is thought to be necessary for the development of leukemia as Cebpa -/-mice with totally absent C/EBPα accumulate immature myeloid progenitors but do not develop AML, 36, 37 and AML patients have not been reported with mutations leading to complete absence of C/EBPα. These results, therefore, suggest that it is the functionally aberrant C/EBPα protein that underlies the hypermethylated profile detected in the CEBPA DM cases. The CEBPA Classic-DM cases provided a framework for assessing the methylation profiles of mutant combinations with at least one non-classic mutant. Only 31% had a methylation profile equivalent to CEBPA Classic-DM , 25% were equivalent to CEBPA WT , and 44% were intermediate between the two. Similar heterogeneity has been reported for gene expression profiles of non-classic cases, with 3 of 7 such cases segregating from cases with classical mutants. 20 This variability is not surprising considering the diversity of the mutant combinations. Although the p30 isoform is thought to play an important role in allowing commitment of the leukemic stem cell to the myeloid lineage, 38 the mechanism by which it promotes AML is not clearly defined. It has a lower affinity for some C/EBP sites than p42 and induces multiple genes that are not affected by p42, [39] [40] [41] and this may have influenced the methylation profile. Knock/in mice expressing just N-terminal mutant developed leukemia but more slowly than the N+C combination. 38, 42 This presumably reflects the additional influence of an aberrant C-terminally mutated protein that might not bind to DNA but can still bind to other C/EBP interacting proteins, such as PU.1 and the SWI/SNF com-D. El-Sharkawi et al. 98 haematologica | 2018; 103(1) plex. Classic C-terminal mutants are associated with hyperproliferation due to loss of cell-cycle regulation and a block in myeloid differentiation. 43 Although knock/in mice with classic C mutant alone do develop leukemia, it is with slower latency than the N+C and mutant N mice. 42 Since these mutants may still bind and potentially sequester other interacting factors, it has been suggested that this could limit the ability of other C/EBPs to rescue the effect of the aberrant C/EBPα, 2 as shown for C/EBPβ in the C/EBPα-deficient situation. 44, 45 This more global cellular impact of the C-terminal mutants may have a greater consequence for signaling events downstream of C/EBPα, which may, therefore, be reflected in the methylation profile.
The methylation profiles did not group according to the predicted functional consequence of the mutant, whether N-or C-terminally mutated. For example, considerable variability was observed for the cases with a C-missense mutation. Of the three classic N plus C-missense combinations assayed, 1 case had a methylation profile equivalent to CEBPA WT and 2 cases had intermediate profiles. Two homozygous C-missense cases grouped with CEBPA WT cases, whereas another homozygous C-missense case grouped with the CEBPA Classic-DM cases. In the 51 cases documented with C-missense mutations in the COSMIC database (http://cancer.sanger.ac.uk/cosmic), most mutations are unique, reported in 1 (n=27, 53%) or 2 (n=9, 18%) patients, and only two residues (R297 and R300) are recorded as being variably mutated in 5 patients. Critical amino acids at the bZIP/DNA interface have been identified from the C/EBPα crystal structure, but many additional hydrogen bonds and van der Waals contacts are implicated in the stabilization of these interactions. 46 Thus, predicting the functional consequence of these mutants is difficult.
From a clinical perspective, risk management requires evaluation of all the available information, and the data presented here suggest that CEBPA DM patients with a nonclassic mutation should not automatically be included in the same favorable-risk prognostic group as CEBPA Classic-DM cases; it might be appropriate to consider them for allogeneic transplantation in first remission. Ultimately, this can only be proven by analysis of clinical trial outcomes and, with the increasing availability of large data sets using targeted next-generation sequencing panels, such analysis may be feasible in the future. This will also promote a better understanding of the mutational background of classic and non-classic CEBPA DM cases and whether there are differences that impact on their prognosis. Our studies also raise the possibility that methylation profiling may identify those non-classic cases that behave in a similar manner to classic mutants; although we cannot directly attribute a causal link between the methylation pattern and chemosensitivity, and further studies are required before this is introduced into clinical practice. 
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